PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Endocyte to Present at Deutsche Bank's 43rd Annual Health Care Conference
WEST LAFAYETTE, Ind. , May 01, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at Deutsche Bank’s 43 rd Annual Health Care
View HTML
Toggle Summary Endocyte Presents Data from its CAR T Platform at American Association for Cancer Research (AACR) Annual Meeting 2018
Late-breaking poster demonstrates EC17/CAR T-cell therapy showed consistent antitumor activity in human xenografts with multiple mechanisms for controlling immune response WEST LAFAYETTE, Ind. , April 16, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing
View HTML
Toggle Summary Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2018
WEST LAFAYETTE, Ind. , March 15, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that four posters will be presented by Endocyte scientists at the American Association for Cancer
View HTML
Toggle Summary Endocyte Nominates Dawn Svoronos for Election to Its Board of Directors and Announces Other Board Developments
Dawn Svoronos, Former President of Merck’s Europe/Canada Region, Brings Significant Commercial Leadership and Board Experience WEST LAFAYETTE, Ind. , March 15, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer
View HTML
Toggle Summary Endocyte to Present at the Cowen and Company 38th Annual Health Care Conference
WEST LAFAYETTE, March 05, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment , today announced that the company’s management team will present at the Cowen and Company 38 th Annual Health Care
View HTML
Toggle Summary Endocyte Announces Closing of Public Offering of Common Stock
WEST LAFAYETTE, March 02, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today the closing of an underwritten registered public offering of 20,535,714 shares of its common stock,
View HTML
Toggle Summary Endocyte Announces Pricing of Public Offering of Common Stock
WEST LAFAYETTE, Ind. , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today the pricing of an underwritten registered public offering of 17,857,143 shares of its
View HTML
Toggle Summary Endocyte Announces Proposed Public Offering of Common Stock
WEST LAFAYETTE, Ind. , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today that it intends to offer and sell shares of its common stock in an underwritten registered public
View HTML
Toggle Summary Endocyte Appoints Patrick Machado, J.D. to Its Board of Directors
– Patrick Machado , Co-founder and Former Chief Business and Financial Officer of Medivation, Brings Significant Experience in Building Value in the Prostate Cancer Space – WEST LAFAYETTE, Ind. , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing
View HTML
Toggle Summary Endocyte Announces Phase 3 VISION Trial and Provides Update on Corporate Strategy and Reports Fourth Quarter and Year End 2017 Financial Results
– Phase 3 VISION Trial Design Finalized for 177 Lu-PSMA-617 Following Successful End of Phase 2 Meeting with the FDA –                    –  Announced Agreement for Clinical Supply of No-Carrier-Added Lutetium with ITM – – Added Experienced Clinical Trial Professionals to Support Execution of
View HTML